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Abstract
Background: Several low and middle-income countries are implementing electronic health records (EHR). In the
near future, EHRs could become an efficient tool to evaluate healthcare performance if appropriate indicators are
developed. The aims of this study are: a) to develop quality of care indicators (QCIs) for type 2 diabetes (T2DM) in
the Mexican Institute of Social Security (IMSS) health system; b) to determine the feasibility of constructing QCIs
using the IMSS EHR data; and c) to evaluate the quality of care (QC) provided to IMSS patients with T2DM.
Methods: We used a three-stage mixed methods approach: a) development of QCIs following the RAND-UCLA
method; b) EHR data extraction and construction of indicators; c) QC evaluation using EHR data from 25,130 T2DM
patients who received care in 2009.
Results: We developed 18 QCIs, of which 14 were possible to construct using available EHR data. QCIs comprised
both process of care and health outcomes. Several flaws in the EHR design and quality of data were identified. The
indicators of process and outcomes of care suggested areas for improvement. For example, only 13.0% of patients
were referred to an ophthalmologist; 3.9% received nutritional counseling; 63.2% of overweight/obese patients
were prescribed metformin, and only 23% had HbA1c <7% (or plasma glucose ≤130 mg/dl).
Conclusions: EHR data can be used to evaluate QC. The results identified both strengths and weaknesses in the
electronic information system as well as in the process and outcomes of T2DM care at IMSS. This information can
be used to guide targeted interventions to improve QC.
Background
The worldwide prevalence of type 2 diabetes (T2DM) is
on the rise, especially in low and middle-income coun-
tries (LMIC), reaching up to 14% of the adult population
in Mexico [1], twice the current global prevalence [2].
T2DM poses considerable challenges to healthcare sys-
tems because it is among the leading causes for ambula-
tory care, hospital admissions and death [3]. In Mexico,
quality of T2DM care has been suboptimal [4,5], health
outcomes poor, [6] and costs of T2DM care and its com-
plications are on the rise [7].
Healthcare for patients with diabetes has both individ-
ual and health system goals. At the individual level, the
goal is to achieve the best possible health outcomes. At
the health system level, the goal is to provide accessible,
high quality, effective, and efficient care. Information
about progression of the disease and processes of care
for patients with T2DM over time is required to assess
whether goals are being accomplished.
The electronic health record (EHR) is a tool that can
provide necessary input for dynamic improvement of
systems for chronic care by a) supporting clinical deci-
sions at the point of care; b) providing routine data to
evaluate the quality of care (QC); and c) facilitating lon-
gitudinal systems research and efficient information
sharing for dynamic care improvement [8,9]. In publicly
financed health care systems, EHR may also help im-
prove transparency and accountability.
LMIC are beginning to use EHR [10]. Argentina, Costa
Rica and Peru use EHR in circumscribed settings, such
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poses [11]. Mexico was the first Latin American country
that introduced an EHR on a large-scale at the Mexican
Institute of Social Security (IMSS). IMSS is a nation-
wide institution providing social security and healthcare
benefits to approximately 47% of the 112 million Mexi-
can people. In 2003, IMSS began to introduce its EHR
and evidence-based clinical guidelines to improve per-
formance of its family medicine clinics [12]. The IMSS
EHR became a key component of the institutional infor-
mation system, which also includes administrative,
member enrollment, pharmacy and other databases.
The IMSS EHR comprises information that could be
used to improve the quality, efficiency and continuity of
care; however, it has not been fully used for these pur-
poses. Little is known about the quality of the data that are
routinely captured and what relevant quality of care indi-
cators (QCIs) can be constructed based on routine data.
T2DM is a complex and dynamic problem that requires
a steady flow of information for healthcare providers to
guide their clinical and managerial decision-making. The
objectives of this project were: a) to develop QCIs for
T2DM in the IMSS health system; b) to determine the
feasibility of constructing QCIs using IMSS EHR data; and
c) to evaluate the QC provided to IMSS patients with
T2DM.
Methods
Design
We used data from four large family medicine clinics
located in Mexico City with a catchment area of 585,536
people. Each clinic had between 15 and 30 physician
offices, a laboratory, and a pharmacy.
IMSS’ EHR consists of several linked databases which
include information on appointments; medical history;
physical examination; clinical encounter notes; aspects of
care and progress for patients with specific conditions
(diabetes, antenatal care, hypertension); social work, occu-
pational health, dietary, and preventive care services. Clin-
ical encounter notes capture the reason for the visit,
symptoms, signs, diagnoses (ICD-10 coded), orders for la-
boratory tests, electronic prescriptions, and disability and
referral information. Data fields contain free-text, nu-
meric, or pre-coded, menu-driven entries. Electronic pre-
scriptions (by menu-driven generic product name) are
linked to the IMSS essential list of medicines and the
clinic’s pharmacy inventory. The laboratory database is
linked to the menu-driven, coded catalog of IMSS labora-
tory exams and contains laboratory test orders. Laboratory
examination results reside in different, unlinked databases.
Stage 1: Development of QC Indicators
To design and validate T2DM QCIs, we used the modi-
fied version of the RAND/UCLA Appropriateness
Method, which comprises scientific evidence and expert
opinion [13,14].
First, we performed a systematic search and review of
the literature on QCIs for T2DM using Marshall’sp r o -
posed method [15]. We searched the following databases:
Medline, Ovid, Cochrane Library, National Guideline
Clearinghouse, CMA Infobase: Clinical Practice Guide-
lines, TRIP database, Institute for Clinical System Im-
provement, ACP Guideline website, American Academy
of Family Physicians, NHS Evidence - National Library of
Guidelines, and IMSS-Clinical Guidelines [16]. The key-
words were “type 2 diabetes mellitus”, “quality of care
indicators”, “clinical guidelines,” and “family medicine” or
“primary care services,”“ diagnosis” and “treatment”.
The review focused on evidence-based care processes
shown to increase the likelihood of achieving the best pos-
sible clinical outcomes, following the criteria proposed by
Saslow et al. [17]. The review included indicators from
the Healthcare Effectiveness Data and Information Set
(HEDIS) [18], as well as those developed by the RAND
Health Research and Institute for Clinical System Im-
provement (ICSI) teams. Indicators for four basic compo-
nents of care for T2DM patients were defined a) timely
screening for complications and comorbidity; b) non-
pharmacological treatment; c) pharmacological treatment;
and d) health outcomes.
Next, we assembled a panel of 8 experts. Panel members
had experience in treating T2DM patients, in conducting
clinical and health systems research, and in developing
clinical guidelines. Each panelist received information
about the study objectives, methodology, literature review
and set of preliminary indicators. Panelists rated indicators
on validity and feasibility according to Shekell’s criteria
[19] by assigning a value from 1 to 9 (1=definitely not
valid or not feasible and 9=definitely valid or feasible). An
indicator was valid when it assessed a process of care for
which there was enough scientific evidence to support the
relationship between the specific process and a potential
health benefit or the assumption that health care profes-
sionals who perform specific care aspects provide better
quality of care than those who do not. An indicator was
feasible when there was a high probability that the
required information to construct the indicator would be
available in a typical health record, or, if not, the lack of in-
formation would represent poor quality of care. Panelists
used these criteria to rate each proposed indicator. An in-
dicator was valid and feasible if its mean score was≥7o n
each domain. Panelists participated in two e-mail rounds
of ranking and two face-to-face panel meetings.
Stage 2: Extraction of routine EHR data to construct
the QCIs
To evaluate whether the indicators defined in Stage 1
could be constructed, we extracted data from a cohort
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clinics. All patients with a diagnosis of T2DM according
to the International Classification of Diseases, Tenth Re-
vision (ICD-10) codes E111-E119, E140-E149, and E14X
in one of three EHR diagnosis fields, who were older
than 19 years of age and visited a family doctor at least
once during 2009 were eligible.
For the cohort of patients with T2DM, we extracted
EHR and laboratory data from the participating Family
Medicine Clinics (FMCs) for calendar year 2009 and cre-
ated an analytic dataset with the following variables:
a. Variables from the EHR: general patient
characteristics (age, sex, schooling, marital status,
membership (subscriber/dependent and employment
status); medical history (age at onset and duration of
T2DM, history of hypertension, other cardiovascular
diseases, or dyslipidemia; chronic complications
[peripheral vascular disease, nephropathy,
retinopathy, and peripheral neuropathy]; physical
measurements (weight, height, and blood pressure);
nutritional status (at the beginning and at the end of
the year) as measured by body mass index (BMI)
(underweight [BMI <18.5 kg/m
2], normal weight
[BMI 18.5 - 24.9 kg/m2], overweight [BMI 25.0 -
29.9 kg/m
2], obese [BMI ≥30.0 kg/m
2]); clinical care
(number of visits to the family doctor, referral to an
ophthalmologist and/or dietitian); prescriptions
(insulin and oral hypoglycemic drugs [metformin,
glibenclamide, acarbose, rosiglitazone or
pioglitazone]; other drugs [acetylsalicylic acid,
statins and angiotensin converting enzyme inhibitors
or angiotensin-receptor blockers]); laboratory tests
ordered.
b. Variables from the laboratory database: dates and
measured values of hemoglobin A1c (HbA1c),
fasting blood glucose, and total cholesterol.
We queried the relational EHR and laboratory database
tables of each clinic using standard queries in structured
query language (SQL) to retrieve data from tables and cre-
ate a new analytic database. We then assessed the data for
completeness, consistency and accuracy. We predefined
non-plausible lowest values for the following variables:
blood pressure (systolic blood pressure <50 mmHg or
>250 mmHg and diastolic blood pressure <40 mm Hg or
>200 mmHg [20]); height (<130 cm or >250 cm), weight
(<30 kg [21] or >200 kg), HbA1C (<3.0), fasting blood
glucose (<37 mg/dl); and total cholesterol (<100 mg/dl).
All non-plausible values were excluded from the analysis.
We used the SAS statistical package (V9.2) to construct
complex variables from the extracted data. We validated
the extracted data by comparing a sample of 80 records in
the EHR system with our final dataset. The comparisons
were made reviewing data from individual EHR with the
extracted data.
Stage 3: Evaluation of T2DM quality of care
We described QC indicators by family medicine clinic.
We also characterized clinics by available health personnel
(number of medical doctors, nutritionists, social workers,
and nurses) and number of examination rooms.
The IMSS’ National Commissions of Research and Ethics
reviewed and approved the study protocol.
Results
Stage 1: Development of QC Indicators
Table 1 shows the results of the indicator evaluation
process. Scores ranged from 5.3 to 8.7. Based on the pre-
defined threshold of 7, the panel discarded 5 and accepted
18 indicators; some indicators scored high in validity, but
were not feasible and were then modified. For example,
HbA1c test results were not available in all clinics. There-
fore, the outcome indicator was modified from “T2DM
patients who had HbA1c <7%” to: “T2DM patients who
had HbA1c <7%, or fasting blood glucose ≤130 mg/dl
in the last three measurements”. Similarly, the LDL-
cholesterol indicator was replaced by an indicator based
on total cholesterol, while the indicator of screening for
microalbuminuria was discarded.
Stage 2: Extraction of routine EHR data to construct QCIs
The final list (Table 1) shows that 14 indicators were
programmable with data from the EHR and laboratory
databases. We decided that four indicators could not be
reliably constructed because information was only avail-
able in free-text fields with wide variability in entries.
There was a high percentage of missing data for employ-
ment, schooling, marital status, and duration of diabetes.
Also, weight, height and blood pressure had between 5%
and 24% non-plausible values.
Stage 3: Evaluation of T2DM quality of care
Table 2 presents the main characteristics of the four par-
ticipating FMCs. There were 204 family doctors working
in the clinics; 67 registered nurses, 86 auxiliary nurses, 6
dietitians, and 36 social workers. Three clinics had a sep-
arate department to conduct medical education activities.
In 2009, the clinics covered 585,536 members and depen-
dents, with 437,417 >20 years old; approximately 174,266
patients visited the clinics at least once during 2009, of
whom 25,130 (14% of patients) had a diagnosis of T2DM.
Table 3 presents the characteristics of the T2DM
patients. Most (59%) were women. The average age was
62.3 years. Nearly two in five patients had low education
(39% illiterate or primary school education only); almost
half were married or lived with their partner. Nearly 30%
were housewives; 17% were employed and 10% were
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Indicator Validity Feasibility Result of the
validation process
Programmable in
the EHR
I. Process indicators Average
A. Timely detection of T2D complications and comorbidity in the last year
1. At least one measurement of HbA1c 8.7 7.8 Accepted Programmable
2. Comprehensive foot evaluation 8.7 8.2 Accepted Programmable
3. Referral to the ophthalmologist 8.3 7.7 Accepted Programmable
4. Screening for microalbuminuria through the ratio albumin/creatinine 8.5 5.7 Discarded
5. Measurement of creatinine and rate of glomerular filtration 8.7 5.3 Discarded
6. Screening for dyslipidemia by measuring total cholesterol in patients
without previous diagnosis of dyslipidemia
8.5 7.8 Accepted Programmable
B. Non pharmacological treatment in the last year
7. Smoking cessation counseling for current smokers 8.2 8 Accepted Not Programmable
8. Advise to moderate alcohol consumption 6.0 5.8 Discarded
9. Nutritional counseling provided by the nutrition service 7.8 7.8 Accepted Programmable
10. Advise to practice aerobic physical exercise of moderate intensity,
at least 150 minutes per week, unless contraindicated
8.2 8.0 Accepted Not Programmable
11. Registration of adherence to dietary recommendations 8.5 7.0 Accepted Not Programmable
12. Registration of adherence to aerobic physical exercise 8.5 7.0 Accepted Not Programmable
C. Pharmacological treatment in the last three visits
13. Overweight/obese (BMI≥25 kg/m
2) patients who received metformin,
unless contraindicated*
8.7 8.5 Accepted Programmable
14. Patients with HbA1c≥8, or with an average fasting blood glucose
of ≥140 mg/dl in the last 3 months, who had registered: a) recommendations
to modify their diet and physical exercise, b) referral to a social work group;
c) modification in their scheme of treatment.
8.7 6.3 Discarded
15. Patients with HbA1c≥8, or with an average fasting blood glucose of
≥140 mg/dl in the last 3 months, who had registered adherence to
the pharmacological treatment.
8.5 6.8 Discarded
16. Patients with hypertension receiving inhibitors of angiotensin converting
enzyme or angiotensin-receptor blocker, otherwise contraindicated**
8.5 8.5 Accepted Programmable
17. Patients>40 years of age with one or more of the following risk factors:
smoking, hypertension, dyslipidemia, receiving 75-150 mg/day of acetylsalicylic acid,
unless contraindicated***
8.5 8.2 Accepted Programmable
18. Patient with total cholesterol >200 mg/dl and were prescribed statins,
unless contraindicated****
8.2 8.3 Accepted Programmable
II. Health outcomes indicators
19. HbA1c <7% or fasting glucose ≤130 mg/dl in the last 3 measurements 8. 7 8.3 Accepted Programmable
20. Total cholesterol levels<200 mg/dl in the last measurement 8. 7 8.2 Accepted Programmable
21. Blood pressure <130/80 mmHg in the last 3 measurements 8. 7 8.5 Accepted Programmable
22. Overweight/obese (BMI≥25 kg/m
2) patients who lost ≥5% body weight in
the last year
8.0 7. 7 Accepted Programmable
Composed indicator of health outcomes
23. Patients with HbA1c <7%, or fasting glucose ≤130 mg/dl, total cholesterol
levels<200 mg/dl and blood pressure <130/80 mmHg in the last 3 measurements
8.5 7.5 Accepted Programmable
*Contraindications to metformin: a) Renal failure b) respiratory or advanced liver failure c) congestive heart failure, coronary artery disease or advanced
atherosclerosis; d) pregnancy; e) intolerance to metformin.
**Contraindications to inhibitors of angiotensin converting enzyme: intolerance and/or prior treatment failure.
***Contraindications to acetylsalicylic acid in doses of 75-150 mg/day: history of hypersensitivity to aspirin, peptic ulcer disease, and hemophilia.
****Contraindications to statins: hypersensitivity to any component of the drug, active liver disease or unexplained persistent elevations of serum transaminases,
pregnancy and lactation.
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members.
Table 4 lists the clinical conditions and health care
characteristics of the included patients. More than 16%
of those reporting had diabetes for over 15 years; how-
ever, disease duration was mostly missing (44%-77%).
Hypertension was the most frequent comorbidity (60%).
Approximately 31% of patients had a chronic complica-
tion, mostly peripheral vascular disease (14%) followed
by diabetic nephropathy (11%). Only 15% had normal
weight; 36% were overweight and 33% obese.
Patients with T2DM were regular users of health care
services; on average, they had 8.8 visits in 2009. Between
10% and 20% of patients did not receive any hypoglycemic
prescription; most (77%) received 1 or 2 drugs. Metformin
(37%) and glibenclamide (46%) were the most frequently
prescribed medications.
Table 5 reports results for the quality of care indicators.
There were wide variations among clinics. Two clinics had
no HBA1c measurements, while the other two had limited
availability. Indicators of timely detection of complications
varied widely: between 5%-52% of patients received com-
prehensive foot evaluations; 5%-22% were referred to an
ophthalmologist; and 46%-70% were screened for dyslipi-
demia. Only 4% received nutritional counseling. Across
clinics, metformin was prescribed (63%) to a majority of
overweight or obese patients; 57% of patients with
hypertension were prescribed ACE inhibitors; 43% of
patients with risk factors for cardiovascular events received
prophylactic acetylsalicylic acid; and 48% of those with
hypercholesterolemia received a statin.
Approximately 62% of patients had registered results of
blood glucose and total cholesterol tests during 2009; among
those without this information, 22% did not have a glucose
and cholesterol test orders and 16% had the laboratory order
registered, but these patients did not attend to the labora-
tory. After comparing the characteristics of patients with
and without laboratory tests, we did not find statistically sig-
nificant differences regarding sex, age, literacy or occupation,
or co-morbidity. Differences were observed in relation to
Table 3 Type 2 diabetes patients’ general characteristics
Characteristics FMC A FMC B FMC C FMC D Total
n=7184
%
n=6671
%
n=7256
%
n=4019
%
n=25130
%
Female sex 59.3 57.8 58.6 58.2 58.5
Age, years, mean
(standard deviation)
62.9
(12.9)
64.3
(12.8)
61.8
(12.8)
58.5
(12.4)
62.3
(12.9)
Age groups
<30 years 0.6 0.3 0.7 0.9 0.6
30–39 years 3.4 3.1 4.0 5.2 3.8
40–49 years 11.2 9.7 12.6 16.8 12.1
50–59 years 23.8 21.0 24.4 31.2 24.4
60–69 years 28.3 29.6 29.5 26.0 28.6
≥70 years 32.7 36.3 28.8 19.9 30.5
Schooling
Illiterate 16.1 7.5 14.9 9.5 12.4
Primary school 24.3 17.6 37.7 26.9 26.8
Secondary school 11.9 11.5 14.3 10.6 12.3
High school 14.8 17.5 10.4 5.3 12.7
University degree 8.0 12.4 4.3 1.3 7.0
Missing data 0.9 33.5 18.3 46.4 28.7
Marital status
Married or partnership 48.3 39.8 54.5 38.0 46.2
Single or divorced 11.9 12.6 7.9 4.5 9.7
Widow 14.2 12.8 2.9 7.1 13.0
Missing data 25.6 34.7 22.3 50.4 31.0
Employment status
Housewife 32.7 26.1 35.3 17.7 29.3
Employed 19.3 16.3 19.6 12.6 17.5
Unemployed 0.1 0.2 0.1 0.4 0.2
Retired 11.9 12.0 11.4 3.1 10.4
Missing data 36.0 45.4 33.6 66.2 42.6
Insurance status
Subscriber 24.0 25.9 20.6 22.4 23.3
Dependent 76.0 74.1 79.4 77.6 76.7
Source: Family medicine clinics 2009 electronic health record information.
Table 2 Population and clinic characteristics
Population affiliated with
the family medicine clinic
FMC A FMC B FMC C FMC D Total
nnnnn
Total number of members 123,276 149,396 196,513 116,351 585,536
Members per family doctor 2,241 2,449 3,388 3,878 2, 828
Members≥20 years old 95,303 120,579 143,796 77,739 437,417
Members≥20 years old who
attended the clinic at least
once in 2009
45,703 53,370 46,270 28,923 174,266
T2DM patients as percentage
of members ≥20 years old
who attended the clinic at
least once in 2009
7184
15.7%
6671
12.5%
7256
15.7%
4019
13.9%
25130
14.4%
Health personnel and
examining rooms
Family doctors 55 61 58 30 204
Registered nurses 14 26 14 13 67
Ancillary nurses 14 21 35 16 86
Dietitian 2 1 1 2 6
Social workers 9 11 9 7 36
Number of family
doctors’ offices
27 29 30 15 101
Department of
medical education
11103
Source: Family medicine clinics 2009 electronic health record information.
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proportion of patients without laboratory exams had only 1
or 2 visits per year (1.2% overall and 21.5% among patients
without laboratory results) (Data not included in the table).
Among patients with laboratory exams, few had
achieved desired health outcomes: 23% had HbA1c <7%
or fasting glucose ≤130 mg/dl in the last 3 measurements;
52% had total cholesterol <200 mg/dl in the last
Table 4 Clinical conditions and health care characteristics
Medical history FMC A FMC B FMC C FMC D Total
n=7184
%
n=6671
%
n=7256
%
n=4019
%
n=25130
%
Duration of diabetes
<5 years 3.8 2.5 1.6 0.9 2.4
5–10 years 12.3 6.8 5.3 10.3 8.5
11–15 years 11.6 7.3 5.2 7.5 7.9
>15 years 27.5 14.8 10.6 11.1 16.6
Missing data 44.8 68.6 77.3 70.2 64.5
Comorbidity and chronic complications
Hypertensive disease 63.3 68.0 59.2 44.5 60.4
Other cardio-vascular disease 11.2 13.2 6.1) 4.2 9.2
Hyperlipidemia 49.2 44.3 40.2 26.1 41.6
Diabetic chronic complications 29.9 29.5 38.1 27.0 31.7
Type of chronic complication
Peripheral vascular disease 8.9 6.8 26.8 14.9 14.5
Diabetic nephropathy 14.5 10.4 8.1 8.2 10.6
Diabetic retinopathy 7.0 12.1 6.8 4.4 7.9
Peripheral neuropathy 5.6 6.0 3.6 4.3 4.9
Nutritional status
Nutritional status at the end of the year
Under weight (<18.5 kg/m
2) 0.3 0.5 0.2 0.3 0.3
Normal weight (BMI18.5- 24.9 kg/m
2) 16.4 17.9 14.2 13.5 15.7
Overweight (BMI 25.0 - 29.9 kg/m
2) 35.8 35.4 36.3 36.2 35.9
Obesity (BMI ≥30.0 kg/m
2) 33.9 31.7 35.3 34.2 33.8
Missing data 13.6 14.5 14.0 15.8 14.3
Health care characteristics
Number of visits of the patient to the family doctor,
mean (standard deviation)
8.5 (4.4) 9.6 (5.0) 8.7 (4.5) 7.9 (4.1) 8.8 (4.6)
Hypoglycemic prescriptions
Number of hypoglycemic prescriptions
None 20.5 18.8 14.1 9.9 16.5
1 37.1 40.9 32.3 34.0 36.2
2 38.1 37.2 43.0 46.9 40.7
≥3 4.3 3.1 10.5 9.1 6.5
Type of hypoglycemic drugs
Metformin 57.2 62.3 65.3 67.1 37.5
Glibenclamide 51.8 46.9 58.7 61.7 45.9
Acarbose 3.3 3.2 12.5 9.7 7.0
Thiazolidinedione 0.0 0.0 1.5 0.0 0.4
Insulin 14.1 12.4 12.5 17.4 13.7
Source: Family medicine clinics 2009 electronic health record information.
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the last 3 measurements; 13% of overweight or obese
patients had lost ≥5% body weight in the last year; and
only 1% of patients reached the combined therapy goals
for blood glucose, cholesterol and blood pressure control.
Discussion
Our results suggest that it is feasible to a) develop T2DM
QCIs applicable in the context of a middle-income coun-
try; b) measure the QCIs using routinely collected data
from a widely implemented EHR system; and c) identify
aspects of care for T2DM patients that are in need of im-
provement. Our work highlights the potential of routine
EHR data to contribute to chronic care quality improve-
ment, as well as the need for attention to the quality and
completeness of electronic data. These findings are im-
portant in the global context of rapidly increasing preva-
lence of chronic conditions, particularly in low and
middle-income countries, which require regular monitor-
ing of processes and outcomes of care to ensure wise use
Table 5 Indicators of quality of care
Indicators FMC A FMC B FMC C FMC D Total
I. Process of care n=7184
%
n=6671
%
n=7256
%
n=4019
%
n=25130
%
A. Timely detection of T2D complications and comorbidity in the last year
At least one measurement of HbA1c 9.0 16.9 Not available Not available 7.1
Comprehensive foot evaluation 51.9 28.2 24.6 5.4 30.3
Referral to the ophthalmologist 22.2 14.2 7.0 5.4 13.0
Screening for dyslipidemia by measuring total cholesterol in
patients without previous diagnosis of dyslipidemia
3653 3714 4336 2971 14674
65.4 54.7 45.6 70.0 57.8
B. Non-pharmacological treatment in the last year n n n n n
%% % % %
Nutritional counseling provided by the nutrition service 7184 6671 7256 4019 25130
1.8 5.5 4.9 3.0 3.9
C. Pharmacological treatment in the last three visits n n n n n
%% % % %
Overweight/obese (BMI≥25 kg/m
2) patients who received metformin,
unless contraindicated
5066 4437 5216 2840 17559
57.2 63.0 66.7 67.6 63.2
Patients with hypertension receiving inhibitors of angiotensin converting
enzyme or angiotensin-receptor blocker, unless contraindicated
4545 4536 4298 1787 15172
46.0 56.8 58.9 66.1 57.4
Patients>40 years of age with one or more of the following risk factors:
smoking, hypertension, dyslipidemia, receiving 75-150 mg/day of
acetylsalicylic acid, unless contraindicated
5242 5035 4904 2076 17257
45.8 32.0 46.2 58.9 43.4
Patient with total cholesterol >200 mg/dl and were prescribed statins,
unless contraindicated
2436 1998 2197 1233 7864
55.6 43.9 49.1 36.9 47.9
II. Health outcomes n n n n n
%% % % %
HbA1c <7% or fasting glucose ≤130 mg/dl in the last 3 measurements 4644 3560 4563 2816 15583
23.0 32.5 19.2 17.9 23.1
Total cholesterol levels<200 mg/dl in the last measurement 5097 4168 4125 3008 16398
52.2 52.1 46.7 59.0 52.0
Blood pressure <130/80 mmHg in the last 3 measurements 7088 6587 7247 4011 24933
12.3 8.5 14.1 5.7 10.8
Overweight/obese (BMI≥25 kg/m2) patients who lost ≥5% body
weight in the last year
5066 4437 5216 2840 17559
13.4 14.7 12.6 12.5 13.3
Patients with HbA1c <7%, or fasting glucose ≤130 mg/dl, total cholesterol
levels<200 mg/dl and blood pressure <130/80 mmHg in the last
3 measurements
4272 3123 3479 2516 13390
1.8 1.7 1.2 0.6 1.4
Source: Family medicine clinics information from 2009 electronic health record. The analysis included 12 months.
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less than optimal uses of electronic health information
systems for routine monitoring of care processes and out-
comes [22,23].
A) QCIs in the context of a middle-income country health
care system
Most published QCIs have been constructed for healthcare
systems in high-income countries. Using the same QCIs
across countries would facilitate international comparisons
[24]. However, QCIs should be adjusted according to na-
tional variations in financing, structure, and provision of
healthcare services, and differences in the characteristics
of populations across countries. We originally intended to
adopt the HEDIS indicators [18] used by more than 90%
of America's health plans to measure performance of care
and services. However, since HbA1c, LDL-cholesterol tests
and nephropathy screening are not established standards
at IMSS family medicine clinics, we needed to develop
contextually suitable indicators. Our process for develop-
ing, measuring, validating, and reporting QC indicators
may be informative in other developing countries.
B) measuring QCIs using routinely collected data from a
widely implemented EHR system
The EHR did not contain all data elements needed to
identify the denominator population of members with
diabetes or to construct the identified QCIs. Clinical ser-
vices at IMSS’ FMCs are almost paperless; all informa-
tion is electronically stored. Our results indicate that
there are shortcomings in the electronic information,
possibly related to flaws in its design and the limited use
of some EHR fields. While we generated rules and algo-
rithms to identify plausible values and exclude records
with missing values from the analysis, it is crucial for
IMSS to improve its electronic record system for quality
monitoring to become a routine process. This would in-
clude maintaining a reliable registry of patients with im-
portant chronic illnesses like diabetes.
We used a conservative approach to manage missing
data, by not including cases with missing information in
the analysis. This decision was supported by results from
comparisons of socio-demographic characteristics of
patients with and without laboratory results, which did
not have statistically significant differences; we also took
into account that the size of the sample was large, thus
reducing the number of cases would not reduce statis-
tical power. However, the validity and generalizability of
our results are limited to the extent that there was bias
in exclusion of members without visits during the obser-
vation year or without data needed to measure QCIs.
To progress to a robust eHealth system, it will be neces-
sary to analyze in-depth the functionality and quality of the
EHR, develop decision-support systems, and strengthen
linkages between the EHR and other electronic applica-
tions, such as laboratory and pharmacy databases.
C) identifying aspects of diabetes care in need of
improvement
Complex healthcare institutions require ongoing evalu-
ation of their performance. In Mexico, evaluating QC
based on EHR data is novel and promising, given the
high cost, lengthy process, and lack of scale of more typ-
ical paper-based evaluations. The lack of complete data
notwithstanding, we identified important aspects of care
that require improvement. IMSS clinics have low rates
of use of diagnostic tests, including HbA1c, microalbu-
minuria screening and LDL-cholesterol. IMSS’ current
model of care relies heavily on family medicine doctors.
As our results show, patients have limited access to die-
titians, social workers, nurses and other specialists, hin-
dering the integrated multi-specialty care patients with
chronic conditions require to ensure the best possible
outcomes [25,26].
Our results are comparable to those from studies within
Mexico and elsewhere. In a study conducted in Mexico,
66.3% of T2DM patients did not have good metabolic con-
trol, although those with access to healthcare had better
health outcomes. The European Core Indicators Diabetes
Project included 19 countries [27]; its results showed wide
variability in QCIs among them: HbA1c testing ranged
from 51% (Ireland) to 99% (France and the Netherlands);
lipid measurements from 45% (Ireland) to 99% (the Neth-
erlands); and eye examinations from 12% (Ireland) to 84%
(The Netherlands). In India, only 13% of T2DM patients
had at least one HbA1c measurement, 16.2% had an eye
examination, 3.1% foot examination, 8.3% nutritional
counseling, 32.1% serum cholesterol estimation and 17.5%
were prescribed aspirin; [28]. Rates of HbA1c>7% varied
from 32% (Ireland) to 83% (Cyprus); total cholesterol>5
mmol/l ranged from 14% (Ireland) to 68% (Cyprus); blood
pressure>140/90 mmHg, from 17% (France) to 46%
(Sweden). [27] The QUALIDIAB network [29] in Argen-
tina, Brazil, Chile, Colombia, Paraguay, and Uruguay
reported that 43% of patients had blood glucose level of
<7.7 mmol/L and the proportion of patients reaching
combined treatment goals for blood glucose, cholesterol
and blood pressure ranged from 1% in Mexico to almost
12% in the United States [30]. These variations should give
rise to continued assessment and improvement efforts.
While this study included information from only four
clinics, we found important differences between them;
for example, two clinics did not have HbA1c data, point-
ing to heterogeneity in care processes even within the
same health delivery system. Further research studies
should examine ways to reduce these differences. Al-
though the study clinics may not represent the QC that
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reviews (with smaller sample sizes) are similar [4,5].
Our results will serve as input to subsequent improve-
ments of the IMSS EHR. The health system in which the
EHR is used has a heavy clinical workload (20–25 patients
per doctor per 6 hours of consultations, or 15–18 minutes
per patient). In this context, the EHR can either hinder or
facilitate care. The EHR was originally designed to gather
routine clinical information to facilitate the daily work of
family doctors and yield epidemiological information. Our
study supports the notion that data from the EHR can be
used to evaluate quality of care. Further, the EHR could
potentially serve other purposes, such as a decision sup-
port system to guide clinicians through gathering relevant
patient information, including risk factors and health sta-
tus, and provide drug dosing guidelines and support tools.
However the IMSS EHR does not yet include decision
support systems. These should be developed as part of the
advancement of the EHR. The experience of Mexico in
the use of the EHR to evaluate quality of care can be of
value for other low and middle-income countries that aim
to improve their e-health capabilities.
Conclusions
This study demonstrated that it was feasible to evaluate
QC for T2DM patients by using EHR data. Evaluating
QC using EHR information can identify the performance
of individual clinics or individual providers, guide future
interventions aimed at improving QC and evaluate
whether these interventions achieve their expected aims.
A well designed EHR, which should include rigorous
data-entry and data quality monitoring would improve the
capabilities to evaluate and monitor processes and out-
comes of care, which in turn would provide useful feed-
back to authorities, healthcare personnel and patients. It
also can serve to make comparisons among clinics, health
care systems or countries.
From the clinicians’ perspective, EHR design and use
should improve its functionality for the daily work, for
example as a clinical decision-making tool, and as a reli-
able source to provide feedback to the providers.
Competing interests
The authors declare that they have no competing interests.
Acknowledgments
We thank the medical directors of the participating clinics for their
collaboration in the study. We appreciate the panel of experts who
participated in the rating of quality of care indicators.
Author details
1Division of Social Protection and Health, Inter-American Development Bank,
Washignton, USA.
2Epidemiology and Health Services Research Unit CMN
Siglo XXI, Mexican Institute of Social Security, México, DF, Mexico.
3Centre for
Health Services and Policy Research, School of Population and Public Health,
The University of British Columbia, Vancouver, Canada.
4Department of
Population Medicine and WHO Collaborating Center in Pharmaceutical
Policy, Harvard Medical School and Harvard Pilgrim Health Care Institute,
Boston, MA, USA.
5Unidad de Investigación en Epidemiología Clínica,
Hospital Regional 1 Carlos MacGregor Sánchez Navarro, IMSS, México, DF,
México.
6División de Innovación de la Coordinación de Educación en Salud,
IMSS, México, DF, Mexico.
Authors’ contributions
RPC conceptualized and designed the study, coordinated the fieldwork and
wrote the article. SVD conducted the literature review, coordinated the
development, definitions, and programming of the indicators, conducted the
statistical analysis, and interpreted the data and contributed to drafting the
article. MSO programmed the indicators and collaborated on the analysis;
ML participated in assessing data quality and programming the indicators
and reviewed critically the results and paper. AHP participated in the
development of the study. JE and FEL participated in the design of the
indicators and reviewed the paper for significant intellectual content. DR-D
collaborated on conceptualizing and designing the study, participated in the
development of the study and critically reviewed the paper. AKW
collaborated on conceptualizing and designing the study, participated in the
development of the study, reviewed the results and contributed to drafting
the article. All authors approved the final manuscript.
The opinions expressed are those of the authors and do not necessarily
represent the views of their institutions.
Received: 30 November 2011 Accepted: 6 June 2012
Published: 6 June 2012
References
1. Villalpando S, Shamah-Levy T, Rojas R, Aguilar-Salinas CA: Trends for type 2
diabetes and other cardiovascular risk factors in Mexico from
1993–2006. Salud Publica Mex 2010, 52:S72–S79. suppl 1.
2. Shaw JE, Sicree RA, Zimmet PZ: Global estimates of the prevalence of
diabetes for 2010 and 2030. Diabetes Res Clin Pract 2010, 87:4–14.
3. Rulla JA, Aguilar-Salinas C, Rojas R, Rios-Torres JM, Gómez-Pérez FJ, Olaiz G:
Epidemiology of type 2 diabetes in Mexico. Arch Intern Med 2005, 36:188–196.
4. Salinas-Martínez AM, Amaya-Alemán MA, Arteaga-García JC, Núñez-Rocha
GM, Garza-Elizondo ME: Technical efficiency in primary care for patients
with diabetes. Salud Publica Mex 2009, 51:48–58.
5. Díaz-Apodaca BA, de Cosío FG, Canela-Soler J, Ruiz-Holguín R, Cerqueira MT:
Quality of diabetes care: a cross-sectional study of adults of Hispanic
origin across and along the United States-Mexico border. Rev Panam
Salud Publica 2010, 28:207–213.
6. Vázquez-Martínez JL, Gómez-Dantés H, Fernández-Cantón S: Diabetes
mellitus en población adulta del IMSS. Resultados de la Encuesta
Nacional de Salud 2000. Rev Med Inst Mex Seguro Soc 2006, 44:13–26.
7. Arredondo A, Zuñiga A: Economic Consequences of Epidemiological
Changes in Diabetes in Middle-Income Countries: The case of Mexico.
Diabetes Care 2004, 27:104–109.
8. McGlynn EA, Damberg CL, Kerr EA, Brook RH: Health Information Systems
Design Issues and Analytic Applications. Santa Monica: Rand Health; 1998.
9. Car J, Black A, Anandan C, Cresswell K, Pagliari C, McKinstry B, Procter R, Majeed
A, Sheikh A: The impact of eHealth on the quality and safety of healthcare.I n
A Systemic Overview & Synthesis of the Literature Report for the NHS Connecting for
Health Evaluation Programme.; 2008. Available at: http://www.haps.
10. Fernández A, Oviedo E: Salud electrónica en América Latina y el Caribe:
avances y desafíos. Santiago de Chile: CEPAL; 2010.
11. Williams F, Boren SA: The role of the electronic medical record (EMR) in
care delivery development in developing countries: a systematic review.
Inform Prim Care 2008, 16:139–145.
12. Pérez-Cuevas R, Ruiz B, Reyes H, Pedrote B, Massa R, Vargas L, Sánchez L,
Estrada C, Michaus F, Castro A, Muñoz O: Implementation and evaluation
of the Family Medicine Improvement Process experimental model.I n
Family medicine at the dawn of the 21st Century. Edited by García-Peña C,
Muñoz O, Durán L. Mexico: IMSS; 2005:55–74.
13. Brook RH, Chassin MR, Fink A, Solomon DH, Kosecoff J, Park RE: A method
for the detailed assessment of the appropriateness of medical
technologies. Inn J Technol Assess Health Care 1986, 2:53–63.
14. Campbell SM, Hann M, Hacker J, Roland MO: Quality assessment for three
common conditions in primary care: validity and reliability of review
criteria developed by expert panels for angina, asthma and type 2
diabetes. Qual Saf Health Care 2002, 11:125–130.
Pérez-Cuevas et al. BMC Medical Informatics and Decision Making 2012, 12:50 Page 9 of 10
http://www.biomedcentral.com/1472-6947/12/5015. Marshall M, Roland M, Campbell S, Jirk S, Reeves D, Brook R, Shekelle PG:
Measuring general practice. A demonstration project to develop and test a set
of primary care quality indicators. London: The Nuffield Trust; 2003.
16. Instituto Mexicano del Seguro Social. Dirección de Prestaciones Médicas:
Guía de Práctica Clínica para el Diagnóstico y Tratamiento de la Diabetes
mellitus tipo 2 en el Primer Nivel de Atención. México DF:; 2009.
17. Saslow D, Runowicz CD, Solomon D, Moscicki AB, Smith RA, Eyre HJ, Cohen
C: American Cancer Society Guideline for the Early Detection of Cervical
Neoplasia and Cancer. CA Cancer J Clin 2002, 52:342–362.
18. National Committee for Quality Assurance: HEDIS 2010 vol. 2 Technical
specifications for Physician Measurement. Washington DC: NCQA; 2010.
19. Shekelle PG, MacLean CH, Morton SC, Wenger NS: Assessing care of
vulnerable elders: methods for developing quality indicators. Ann Intern
Med 2001, 135:647–652.
20. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL, Jones
DW, Materson BJ, Oparil S, Wright JT, Roccella EJ: Seventh report of the
Joint National Committee on Prevention, Detection, Evaluation, and
Treatment of High Blood Pressure. Hypertension 2003, 42:1206–1252.
21. McDowell MA, Fryar CD, Ogden CL, Flegal KM: Anthropometric Reference
Data for Children and Adults: United States, 2003–2006.I nNational
health statistics reports; no 10. Hyattsville, MD: National Center for Health
Statistics; 2008.
22. O’Connor P, Crain AL, Rush W, Sperl-Hillen J, Gutenkauf J, Duncan J: Impact
of Electronic Medical Record on Diabetes Quality of Care. Ann Fam Med
2005, 3:300–306.
23. Fraser HS, Blaya J: Implementing medical information systems in
developing countries, what works and what doesn't. AMIA Annu Symp
Proc 2010, 2010:232–236.
24. Steel N, Melzer D, Shekelle PG, Wenger NS, Forsyth D, McWilliams BC:
Developing quality indicators for older adults: transfer from the USA to
the UK is feasible. Qual Saf Health Care 2004, 13:260–264.
25. Pérez-Cuevas R, Reyes-Morales H, Doubova SV, Zepeda Arias M, Díaz
Rodríguez G, Peña Valdovinos A, Muñoz Hernández O: Comprehensive
diabetic and hypertensive patient care involving nurses working in
family practice. Rev Panam Salud Publica 2009, 26:511–517.
26. Ortiz-Domínguez ME, Garrido-Latorre F, Orozco R, Pineda-Pérez D,
Rodríguez-Salgado M: Sistema de Protección Social en Salud y calidad de
la atención de hipertensión arterial y diabetes mellitus en centros de
salud. Salud Publica Mex 2011, 53:S436–S444.
27. EuCID: Final Report European Core Indicators in Diabetes Project.; 2008.
Available at: http://ec.europa.eu/health/ph_projects/2005/action1/docs/
action1_2005_frep_11_en.pf.
28. Nagpal J, Bhartia A: Quality of diabetes care in the middle- and high-
income group populace: the Delhi Diabetes Community (DEDICOM)
survey. Diabetes Care 2006, 29:2341–2348.
29. Gagliardino JJ, de la Hera M, Siri F, Grupo de Investigación de la Red
QUALIDIAB: Evaluation of the quality of care for diabetic patients in Latin
America. Rev Panam Salud Publica 2010, 10:309–317.
30. Gakidou E, Mallinger L, Abbott-Klafter J, Guerrero R, Villalpando S, Ridaura
RL, Aekplakorn W, Naghavi M, Lim S, Lozano R, Murray CJ: Management of
diabetes and associated cardiovascular risk factors in seven countries: a
comparison of data from national health examination surveys. Bull World
Health Organ 2011, 89:172–183.
doi:10.1186/1472-6947-12-50
Cite this article as: Pérez-Cuevas et al.: Evaluating quality of care for
patients with type 2 diabetes using electronic health record information
in Mexico. BMC Medical Informatics and Decision Making 2012 12:50.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Pérez-Cuevas et al. BMC Medical Informatics and Decision Making 2012, 12:50 Page 10 of 10
http://www.biomedcentral.com/1472-6947/12/50